Laura Schreier

Laura Schreier

Auto-generated profile, based on publicly available information

Laura Schreier

Laboratorio de Lípidos y Aterosclerosis, Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in International Journal of Food Sciences and Nutrition
Verified
Journal Article
Closed access
EMElisa V. Macri
Elisa V. Macri
FLFima Lifshitz
Fima Lifshitz
EAEstefania Alsina
Estefania Alsina
NJNatalia Juiz
Natalia Juiz
VZValeria Zago
Valeria Zago
SFSILVIA MARIA FRIEDMAN
SILVIA MARIA FRIEDMAN
The effects of replacing dietary saturated fat by different monounsaturated fatty acid (ω-9MUFA) sources on serum lipids, body fat and bone in growing hypercholesterolemic rats were studied. Rats received one of the six different diets: AIN-93G (control, C); extra virgin olive oil (OO) + C; high-oleic sunflower oil (HOSO) + C or atherogenic diet (AT) for 8 weeks; the remaining two groups received AT for 3 weeks and then, the saturated fat was replaced by an oil mixture of soybean oil added with OO or HOSO for 5 weeks. Rats consuming MUFA-rich diets showed the highest body fat, hepatic index and epididymal, intestinal and perirenal fat, and triglycerides. T-chol and non-HDL-chol were increased in HOSO rats but decreased in OO rats. Bone mineral content and density were higher in both OO and HOSO groups than in AT rats. This study casts caution to the generalization of the benefits of MUFA for the treatment of hypercholesterolemia.

1 October 2020 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
Ana Catarina AlvesAna Catarina Alves
Ana Catarina Alves
RARodrigo Alonso
Rodrigo Alonso
JDJose luis Díaz Díaz
Jose luis Díaz Díaz
AMAna Margarida Medeiros
Ana Margarida Medeiros
CJCinthia E Jannes
Cinthia E Jannes
RSRaul D Santos
Raul D Santos
Characterize homozygous familial hypercholesterolemia (HoFH) individuals from Iberoamerica. Approach and Results: In a cross-sectional retrospective evaluation 134 individuals with a HoFH phenotype, 71 adults (age 39.3±15.8 years, 38.0% males), and 63 children (age 8.8±4.0 years, 50.8% males) were studied. Genetic characterization was available in 129 (96%). The majority (91%) were true homozygotes (true HoFH, n=79, 43.0% children, 46.8% males) or compound heterozygotes (compound heterozygous familial hypercholesterolemia, n=39, 51.3% children, 46.2% males) with putative pathogenic variants in the LDLR. True HoFH due to LDLR variants had higher total (P=0.015) and LDL (low-density lipoprotein)-cholesterol (P=0.008) compared with compound heterozygous familial hypercholesterolemia. Children with true HoFH (n=34) tended to be diagnosed earlier (P=0.051) and had a greater frequency of xanthomas (P=0.016) than those with compound heterozygous familial hypercholesterolemia (n=20). Previous major cardiovascular events were present in 25 (48%) of 52 children (missing information in 2 cases), and in 43 (67%) of 64 adults with LDLR variants. Children who are true HoFH had higher frequency of major cardiovascular events (P=0.02), coronary heart (P=0.013), and aortic/supra-aortic valve diseases (P=0.022) than compound heterozygous familial hypercholesterolemia. In adults, no differences were observed in major cardiovascular events according to type of LDLR variant. From 118 subjects with LDLR variants, 76 (64%) had 2 likely pathogenic or pathogenic variants. In 89 subjects with 2 LDLR variants, those with at least one null allele were younger (P=0.003) and had a greater frequency of major cardiovascular events (P=0.038) occurring at an earlier age (P=0.001). There was a high frequency of cardiovascular disease even in children. Phenotype and cardiovascular complications were heterogeneous and associated with the type of molecular defect.

1 August 2022 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
MBMagalí Barchuk
Magalí Barchuk
PAPatricia Ancel
Patricia Ancel
VMVerónica Miksztowicz
Verónica Miksztowicz
EDElisa Doukbi
Elisa Doukbi
LSLjubica Svilar
Ljubica Svilar
GBGabriela Berg
Gabriela Berg
Background: Epicardial adipose tissue (EAT) contributes to coronary artery disease (CAD). EAT presents a specific lipidomic signature, showing increased ceramides and other proinflammatory lipids content. Besides, LPL (lipoprotein lipase) activity in EAT would contribute to its expansion, supplying fatty acids to the tissue. Our aim was to evaluate the relations between LPL activity, regulators of LPL, and ceramides in EAT from CAD patients. Methods: We studied patients undergoing coronary bypass graft (CAD, n=25) and patients without CAD (no CAD, n=14). EAT and subcutaneous AT (SAT) were obtained, tissue LPL activity and its regulator’s expression (ANGPTL4, GPIHBP1 [glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1], and PPARγ [peroxisomal proliferator–activated receptor γ]) were assessed. Tissue lipidomes were evaluated by UHPLC-MS, in positive and negative ionization modes. Results: LPL activity was higher in EAT from CAD ( P <0.001), and in EAT than SAT in both groups ( P <0.001). ANGPTL4 levels were lower, GPIHBP1 and PPARγ levels were higher in EAT from CAD ( P <0.001). In both groups, EAT exhibited more ceramide ( P =0.01), directly associated with LPL activity, being the strongest association with Cer18:1/24:1 ( P <0.001). EAT Cer18:1/16:0 to Cer18:1/24:0 and Cer18:1/24:1 to 18:1/24:0 ratios were higher in CAD ( P =0.03; P <0.001, respectively), the latter directly associated with LPL activity ( r =0.63, P <0.001) GPIHBP1 levels ( r =0.68, P <0.001), and inversely to EAT ANGPTL4 expression ( r =−0.49, P =0.03). Pairwise partial correlation network showed associations among bioactive lipids and LPL and its regulators ( P <0.001 in all cases). Conclusions: The association between LPL activity, total ceramide, and the atherogenic ceramide ratios highlights the importance of the enzyme and these bioactive lipids contributing to the different metabolic profile of EAT in CAD.

1 January 2025 in Journal of Lipid and Atherosclerosis
Verified
Journal Article
Open access
PDF file
COCarolina Olano
Carolina Olano
GFGregorio Fariña
Gregorio Fariña
Morena WiszniewskiMorena Wiszniewski
Morena Wiszniewski
JMJimena Medel
Jimena Medel
CMCelina Morales
Celina Morales
VZValeria Zago
Valeria Zago
Olano C, et al. J Lipid Atheroscler. 2025 Jan;14(1):106-119. https://doi.org/10.12997/jla.2025.14.1.106

20 March 2020
Verified
Book Chapter
Closed access
PDF file
GBGabriela Brenta
Gabriela Brenta
LSLaura Schreier
Laura Schreier

1 June 2018 in Atherosclerosis Supplements
Verified
Journal Article
Closed access
MBMagalí Barchuk
Magalí Barchuk
VMVerónica Miksztowicz
Verónica Miksztowicz
GLGraciela Lopez
Graciela Lopez
MRMiguel Rubio-Godoy
Miguel Rubio-Godoy
LSLaura Schreier
Laura Schreier
GBGabriela Berg
Gabriela Berg